Fahar Merchant - Medicenna Therapeutics Cor Chairman, Founder

MDNA Stock

CAD 1.04 0.03 2.97%

Insider

Fahar Merchant is Chairman, Founder of Medicenna Therapeutics Corp

Age	68
Phone	416 648 5555
Web	https://www.medicenna.com

Medicenna Therapeutics Cor Management Efficiency

The company has return on total asset (ROA) of (0.4208) % which means that it has lost $0.4208 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4909) %, meaning that it generated substantial loss on money invested by shareholders. Medicenna Therapeutics Cor's management efficiency ratios could be used to measure how well Medicenna Therapeutics Cor manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Medicenna Therapeutics Cor to Peers

Predict price of Medicenna Therapeutics Cor

Medicenna Therapeutics Corp has accumulated 13.94 M in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Medicenna Therapeutics Cor has a current ratio of 26.22, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Medicenna Therapeutics Cor until it has trouble settling it off, either with new capital or with free cash flow. So, Medicenna Therapeutics Cor's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medicenna Therapeutics Cor sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medicenna to invest in growth at high rates of return. When we think about Medicenna Therapeutics Cor's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 13 records			INSIDER Age
	Michael Moore	Oncolytics Biotech	N/A
	Rita Laeufle	Oncolytics Biotech	N/A
	Jon Patton	Oncolytics Biotech	N/A
	Allison Hagerman	Oncolytics Biotech	N/A
	CA CA	Oncolytics Biotech	N/A
	MBA MBA	Helix BioPharma Corp	63
	J Lievonen	Oncolytics Biotech	N/A
	Grey Wilkinson	Oncolytics Biotech	N/A
	FACP FACP	Oncolytics Biotech	74
	Janet CA	Aptose Biosciences	N/A
	FCA FCA	Oncolytics Biotech	N/A
	Dr MA	Helix BioPharma Corp	N/A
	Andrew Guttadauro	Oncolytics Biotech	57

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines and Superkines for the treatment of cancer. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. MEDICENNA THERAPEUTICS operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 7 people. Medicenna Therapeutics Corp (MDNA) is traded on Toronto Exchange in Canada and employs 16 people. Medicenna Therapeutics Cor is listed under Biotechnology category by Fama And French industry classification.

Management Performance

	Return On Equity	-1.49
	Return On Asset	-0.42

Medicenna Therapeutics Cor Leadership Team

Elected by the shareholders, the Medicenna Therapeutics Cor's board of directors comprises two types of representatives: Medicenna Therapeutics Cor inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medicenna. The board's role is to monitor Medicenna Therapeutics Cor's management team and ensure that shareholders' interests are well served. Medicenna Therapeutics Cor's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medicenna Therapeutics Cor's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Fahar Merchant, Chairman, Founder
	MBBS MD, Acting Devel
	MESc BSc, Founder Officer
	MD FCAP, Chief Officer
	CBV CA, Chief Officer
	Samuel MD, Scientific Advisor

Medicenna Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medicenna Therapeutics Cor a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-1.49
	Return On Asset	-0.42
	Current Valuation	51.52 M
	Shares Outstanding	78.22 M
	Shares Owned By Insiders	22.16 %
	Shares Owned By Institutions	12.82 %
	Number Of Shares Shorted	436.62 K
	Price To Book	4.66 X
	EBITDA	(18.67 M)
	Net Income	(25.47 M)

Pair Trading with Medicenna Therapeutics Cor

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medicenna Therapeutics Cor position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicenna Therapeutics Cor will appreciate offsetting losses from the drop in the long position's value.

Moving against Medicenna Stock

0.91	TD	Toronto Dominion Bank	Pair Corr
0.59	TD-PFD	Toronto Dominion Bank	Pair Corr
0.51	RY-PM	Royal Bank	Pair Corr
0.4	LOU	Lucero Energy Corp	Pair Corr
0.39	CAE	CAE Inc	Pair Corr

The ability to find closely correlated positions to Medicenna Therapeutics Cor could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medicenna Therapeutics Cor when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medicenna Therapeutics Cor - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medicenna Therapeutics Corp to buy it.

The correlation of Medicenna Therapeutics Cor is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medicenna Therapeutics Cor moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medicenna Therapeutics Cor moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Medicenna Therapeutics Cor can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Medicenna Stock

Medicenna Therapeutics Cor financial ratios help investors to determine whether Medicenna Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medicenna with respect to the benefits of owning Medicenna Therapeutics Cor security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC